Trump announces nine new drug pricing deals
Analysis based on 38 articles · First reported Aug 18, 2026 · Last updated Sep 04, 2026
The agreements are expected to lower drug prices for U.S. patients and reduce government spending, potentially pressuring pharmaceutical revenues but improving affordability and access. The deals provide tariff relief and regulatory certainty for participating companies, while the broader drug pricing environment remains influenced by the Inflation Reduction Act and market competition.
On August 31, 2026, President Donald Trump announced voluntary drug pricing agreements with nine pharmaceutical companies: Alcon, Astellas Pharma, BeOne Medicines, BridgeBio Pharma, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. These companies agreed to offer most-favored-nation (MFN) pricing to U.S. United States — Medicaid programs and for future innovative medicines, in exchange for tariff relief and exemption from Section 232 pharmaceutical tariffs. The deals bring the total number of MFN agreements to 26, covering about 89% of the branded drug market, and are projected to save Americans over $600 billion over 10 years, according to Trump. The announcement follows earlier agreements with 17 large drugmakers including Pfizer, Eli Lilly, and Amgen. Concurrently, the United States — White House touted a 0.8% decline in prescription drug prices in July, the largest annual drop since 1963, attributing it to these deals and the TrumpRx website. However, drug pricing experts note that other factors, including the Biden-era Inflation Reduction Act's Medicare negotiation provisions and increased generic/biosimilar competition, likely contributed more significantly. The actual impact of the MFN deals remains unclear as contracts are not public and models are not yet implemented. BeOne Medicines separately announced a $300 million onshoring investment in New Jersey, bringing its total U.S. manufacturing investment to over $1 billion. Sun Pharma's agreement also delays potential Section 232 tariffs for over two years, supporting its planned $11.75 billion acquisition of Organon & Co..
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard